関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
生まれながらのフィブリノゲン欠乏症における血栓症のパラドックス:病理学から実践へ
Samin Mohsenian1, Alessandro Casini2, Flora Peyvandi1,3
1Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Research and practice in thrombosis and haemostasis
|August 21, 2025
関連する実験動画
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.1K
06:28Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
6.9K
07:09Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
11.6K
PubMed で要約を見る
まとめ
生まれながらのフィブリノゲン欠乏症 (CFD) は逆説的にフィブリノゲン異常による血栓形成のリスクを高めます. 治療に役立つ証拠は限られているが,出血と凝固のリスクのバランスをとる必要がある.
科学分野:
- 血液学
- 遺伝学
- トロンボシス 研究
背景:
- 生まれつきのフィブリノゲン欠乏症 (CFD) は,フィブリノゲンの量または質に影響を与える珍しい遺伝疾患です.
- 通常は出血と関連しているが,CFDは動脈と静脈血栓症とますます関連している.
- このメカニズムは,血栓のクリアランスの低下,凝固の構造の異常,および線維分解の減少を含む.
研究 の 目的:
- CFDにおける結血病の流行病学,メカニズム,および臨床管理をレビューする.
- 知識のギャップとさらなる研究の必要性を強調する.
主な方法:
- 生まれながらのフィブリノゲン欠乏症における血栓形成に関する既存の証拠の文献レビュー.
- 内在のフィブリノゲン変種と外在の要因を含む提案された病原遺伝的メカニズムの分析.
- 罹患患者の血栓の管理に関する現在の課題とアプローチの検討
主要な成果:
- CFDは,フリートロンビンの増加や繊維分解の障害などのメカニズムを通じて,血栓形成を引き起こす可能性があります.
- 固有の因子 (例えば,特定のフィブリノゲン変種) と外的な因子 (例えば,手術,不動) の両方が,血栓形成の危険に寄与する.
- 治療は複雑で,抗凝固薬とフィブリノゲン置換療法の潜在的なリスクのバランスを求めます.
結論:
- CFDにおける血栓形成は多因性であり,完全に理解されていません.
- CFDにおける血栓形成の臨床管理は困難であり,個別化された治療戦略を必要とします.
- 患者の理解と成果を向上させるにはさらなる研究が不可欠です
ディスフィブリノゲネミア